Table 2 Detection of copy number alterations (CNA) in the plasma by histologic subtype.
From: Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors
CNA positive (%) | Enrolled at initial diagnosis (n = 37) | Enrolled at recurrence (n = 19) | ||
|---|---|---|---|---|
Stage | ||||
Localized (n = 27) | Metastatic (n = 10) | |||
CNA positive (%) | 36 (64%) | 18 (67%) | 8 (80%) | 10 (53%) |
Tumor Type | ||||
Sarcoma (n = 37) | 21 (57%) | 11 (61%) | 6 (75%) | 4 (36%) |
Ewing Sarcoma (n = 13) | 9 (69%) | 4 (57%) | 4 (80%) | 1 (100%) |
Osteosarcoma (n = 17) | 9 (53%) | 4 (67%) | 2 (100%) | 3 (33%) |
Alveolar RMS (n = 2) | 1 (50%) | 1 (50%) | 0 | 0 |
Embryonal RMS (n = 1) | 0 | 0 | 0 | 0 |
Other sarcoma (n = 4) | 2 (50%) | 2 (50%) | 0 | 0 |
Renal Tumor (n = 9) | 8 (89%) | 2 (67%) | 1 (100%) | 5 (100%) |
Wilms tumor (n = 7) | 6 (86%) | 2 (67%) | 1 (100%) | 3 (100%) |
Other (n = 2) | 2 (100%) | 0 | 0 | 2 (100%) |
Hepatic Tumor (n = 4) | 3 (75%) | 3 (75%) | 0 | 0 |
Hepatoblastoma (n = 3) | 2 (67%) | 2 (67%) | 0 | 0 |
Embryonal sarcoma liver (n = 1) | 1 (100%) | 1 (100%) | 0 | 0 |
Malignant Germ Cell Tumor (n = 5) | 4 (80%) | 2 (100%) | 1 (100%) | 1 (50%) |
Thyroid Carcinoma (n = 1) | 0 | 0 | 0 | 0 |
